29 results about "Metaplasia" patented technology

The invention relates to the technical field of biological medicine, in particular to a drug screening model construction method based on airway organs, a model and application. The construction method of the drug screening model of the airway organoid comprises the steps of obtaining 2D airway epithelial cells, culturing the airway organoid, establishing an airway organoid inflammation model and / or establishing an airway organoid mucus secretion / goblet cell metaplasia model. Wherein the model is established according to the culture mode of the airway organ in cooperation with a specific stimulant for proliferation and differentiation. Compared with a traditional animal model, the organ-like model is low in cost and short in construction period, can better simulate the pathological process, can realize airway organ-like culture and establishment of an inflammation model and a mucus secretion / goblet cell metaplasia model at the same time, and has a good application prospect in drug detection of asthma and COPD diseases.

Pyrvinium and its derivatives for reprogramming precancerous mucosa into a noncancerous state are described herein. Furthermore, pyrvinium and its derivatives for reducing the risk of cancer development in organisms containing metaplastic or dysplastic cells are described herein.

The invention relates to the technical field of biological medicine, provides novel application of IL-17a, and particularly relates to application of an IL-17a inhibitor in preparation of a medicine for treating age-related olfactory dysfunction. The research result shows that the expression increase of the IL-17a can trigger an inflammation signal and damage the olfactory function. Administration of the IL-17a inhibitor Y-320 or a neutralizing antibody promotes sensory neuron regeneration in the olfactory epithelium (OE) and reverses age-related respiratory metaplasia. In addition, conditional knockout of IL-17a in T cells can promote olfactory epithelium regeneration by promoting recruitment and differentiation of horizontal basal cells (HBCs) into globular basal cells (GBCs). In general, the research of the invention determines the previously undetermined effect of the IL-17a in olfactory epithelium regeneration and age-related olfactory function defects, and provides evidence for the IL-17a as a potential therapeutic target for olfaction of the elderly.

The invention relates to the technical field of biology, in particular to application of black phosphorus nanosheet hydrogel to preparation of medicine for treating dry eye syndrome. The black phosphorus nanosheet hydrogel can promote tear film healing, treat dry corneal injury and remove active oxygen and free radicals, has an anti-inflammatory effect, inhibits squamous metaplasia, inhibits expression of IL-1beta, K10 and MMP-9 and the like, and provides a new direction for treatment of the dry eye syndrome.

The application belongs to the field of biological medicine, and particularly relates to application of DJ-1 in treatment and diagnosis of bronchial asthma. DJ-1 is used as a target in preparation or screening of drugs for bronchial asthma or allergic inflammation; a drug for treating hyperplasia of goblet cells and mucus metaplasia in bronchial asthma, and an animal model for studying inhibition of differentiation of goblet cells and mucus metaplasia. The application identifies, for the first time, an important role of a signal pathway DJ-1 / Ltc4s, which has not been found in eosinophils and lung epithelial cells before, in differentiation of secretory cells into goblet cells, and finds, for the first time, an inhibitory effect of inhibition of the DJ-1 / Ltc4s signal pathway on differentiation of goblet cells in lung epithelial cells through a large number of studies.

The invention provides a traditional Chinese medicine composition for treating chronic atrophic gastritis and a preparation method thereof. The traditional Chinese medicine composition comprises the following raw material medicines in parts by weight: 280-320 parts of red ginseng; the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 580 to 620 parts of rhizoma atractylodis macrocephalae, 280 to 320 parts of rhizoma zingiberis, 80 to 120 parts of sandalwood, 280 to 320 parts of edible tulip, 580 to 620 parts of concha arcae, 580 to 620 parts of oldenlandia diffusa, 180 to 220 parts of notholirion bulbuliferum and 280 to 320 parts of sea buckthron oil. The total effective rate of the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia is 93%, and the traditional Chinese medicine composition has a remarkable clinical effect on treating chronic atrophic gastritis with intestinal metaplasia clinically.

The invention provides application of combination of an mTOR inhibitor and an EPAS1 inhibitor in preparation of a medicine for treating myeloproliferative tumors, through combined use of the mTOR inhibitor everolimus and the EPAS1 inhibitor PT2385, JAK2V617F mutation-driven metabolic disorder is targeted, metabolic reprogramming is effectively reversed (the lactic acid level is reduced, the alpha-ketoglutaric acid level is increased, and the lactic acid / alpha-KG ratio is corrected), and the treatment effect on myeloproliferative tumors is improved. The JAK inhibitor can be used for treating MPN, synergistically relieving splenomegaly, reversing myelofibrosis and reducing mutation allele load, the curative effect is remarkably superior to that of existing JAK inhibitor single-drug treatment, and an innovative scheme with disease modification potential is provided for MPN.

Disclosed herein are methods for treating Barrett's metaplasia and esophageal adenocarcinoma and methods for determining mutational load as a predictor of the risk of disease progression from Barrett's metaplasia to esophageal adenocarcinoma.

The present disclosure is a telescopic endobronchial stem cell cultivation catheter that comprises a segment catheter (1), a terminal catheter (2), and a respiratory catheter (3) ensuring that ensures the prevention of the progression of COPD and provides early treatment before it progresses to advanced stages, allows the increase of the number of reduced lung parenchyma by means of its inoculation feature in advanced COPD stages, provides the removal of metaplastic cells in the bronchial walls in the application area with the rhythmic inflation-deflation movement by means of the balloons (1.2, 2.2, 3.2) and reduces the risk of future cancer formation, and increases respiratory ventilation by expanding narrowed terminal bronchioles (11) and increasing air flow to the respiratory bronchioles (12).

The invention provides an M2 macrophage exosome loaded canagliflozin nano-drug and application thereof, an M2 macrophage exosome is used as a carrier, and canagliflozin is loaded on the M2 macrophage exosome. The Exo-CANA delivery system is constructed for the first time, the exosomes are small in size, the phagocytosis of mononuclear macrophages can be effectively avoided, the exosomes can freely penetrate through vascular walls and extracellular matrixes, Th2 type airway inflammation, goblet cell metaplasia and pulmonary interstitial collagen deposition can be remarkably improved, and the treatment effect is remarkably superior to that of a CANA single-drug treatment group and an M2-Exos single-drug treatment group.

According to the present invention, strains for preventing gastric cancer have been identified and, in particular, it has been identified that when a microbiome was administered together with H. felis, which is known to cause various gastrointestinal diseases by inducing gastric tissue damage and inflammatory responses, gastric tissue damage and inflammatory responses did not occur. Furthermore, it has been identified that the microbiome suppresses gastric tissue damage when administered even in cases already infected with H. felis. Therefore, the microbiome can be effectively used as a preventive or therapeutic agent for normalizing gastric intestinal metaplasia, which is a precancerous lesion, and for suppressing gastric carcinogenesis.

This invention proposes a grading system for the severity of intestinal metaplasia based on the deformation Transformer. By dividing the endoscopic image into multiple feature units, matching feature unit groups are obtained based on the similarity of the feature units. The feature unit groups are then fused after weight calculation, realizing the deformation of the sampling region in the Transformer. This overcomes the shortcomings of the fixed region sampling in the Transformer, improves the feature extraction capability, and enhances the accuracy of grading the severity of intestinal metaplasia.

A method for detecting methylation status of at least one sequence in a tissue sample of a subject includes providing the tissue sample obtained from the subject, treating the tissue sample to convert DNA sequences within the tissue sample with at least one of enzymatic conversion and chemical conversion to produce a modified sample having converted DNA sequences and replicated the converted DNA. The method further includes amplifying the converted DNA sequences to provide a plurality of converted amplicons and analyzing the plurality of converted amplicons to determine the methylation status of the sample.

It has been identified in the present invention that, in addition to Helicobacter felis, strains causing cell hyperplasia, metaplasia, dysplasia, and the like in gastric tissues. Therefore, a gastric cancer mouse model in which gastric lesions are induced in mice can be provided using a gastric microbial transplantation (GMT) technology, and various gastrointestinal diseases can be diagnosed and the prognosis thereof can be predicted by measuring the concentrations of the strains.

The invention discloses a construction method of a chronic atrophic gastritis precancerous lesion animal model, and the construction method comprises the following specific steps: selecting experimental mice, randomly and averagely dividing the experimental mice into a model group and a blank control group, the experimental mice of the model group drink an MNU solution I by themselves and use an MNU solution II for intragastric administration once a week, and the blank control group normally diets; after modeling, dissecting and taking stomach tissues for later use; the MNU solution I is an N-nitroso-N-methylurea solution with the concentration of 290 mg / L to 310 mg / L; the MNU solution II is an N-nitroso-N-methylurea solution with the concentration of 1.6 g / L to 1.7 g / L; according to the method, 14-week modeling can be achieved, intestinal metaplasia, heterodysplasia and even a small number of cancer cells can occur in 14 weeks, and compared with a traditional MNNG combined multi-factor modeling method, the modeling method has the advantages that the modeling method is simplified, experimental errors and individual differences are reduced, the modeling period is shortened, and the modeling success rate is increased.

Recombinant blood group antigen-binding adhesin (BabA) can be used in a composition to raise humoral immune response i.e. antibodies, that target conserved structural epitopes in the fucosylated blood group antigen Lewis b (Leb) antigen binding domain in the blood group antigen-binding adhesin (BabA). Such broadly Leb-blocking antibodies can reduce the gastric mucosal attachment of Helicobacter pylori (H. pylori) to human gastric mucosa. This approach can be used for preventing and / or alleviating gastric disease in a subject diagnosed with H. pylori infection, said gastric disease chosen from gastroesophageal reflux disease, chronic active gastritis, peptic ulcer diseases, gastric ulcer disease, gastric cancer gastritis and gastric cancer, in particular gastric cancer. It also becomes possible to identify subjects that carry BabA positive H. pylori infections and subjects that are at risk of developing severe gastric disease, such as peptic ulcer diseases, gastric ulcer disease, gastritis with metaplasia and gastric cancer.

The invention discloses a traditional Chinese medicine composition and application thereof, raw material medicines of the traditional Chinese medicine composition comprise first raw material medicines, and the first raw material medicines comprise 10-40 parts by weight of mangnolia officinalis, 10-60 parts by weight of astragalus membranaceus, 10-40 parts by weight of bighead atractylodes rhizome, 10-40 parts by weight of curcuma zedoary, 5-40 parts by weight of rhizoma bletillae and 5-40 parts by weight of rhizoma zingiberis; the raw material medicine of the traditional Chinese medicine composition further comprises a second raw material medicine, and the second raw material medicine is pseudo-ginseng; the weight ratio of the first raw material medicine to the second raw material medicine is (15-17): (1-12). The traditional Chinese medicine composition can effectively relieve digestive tract discomfort symptoms caused by chronic atrophic gastritis, can effectively improve the pathological state of gastrointestinal tract tissues, reverses the pathological states of stomach tissue atrophy, intestinal metaplasia and / or dysplasia and the like, relieves gastrointestinal tract disease symptoms such as poor appetite, abdominal distension, fullness, belching, sour regurgitation and heartburn in the past, and improves the curative effect of chronic atrophic gastritis. And the traditional Chinese medicine composition is simple in taking method, low in dosage and high in clinical value.

The invention belongs to the technical field of medical experimental animal models, and particularly relates to a construction method of a spleen and stomach damp-heat syndrome chronic atrophic gastritis animal model. The construction method comprises the following steps: firstly, performing spleen and stomach damp-heat modeling on a tested animal to obtain spleen and stomach damp-heat syndromes, and then performing chronic atrophic gastritis induction. According to the specific three-step atrophic gastritis induction method, the clinical pathological process of inflammation caused by stimulation, gastric mucosa atrophy caused by damp heat and blood stasis for a long time and intestinal metaplasia can be accurately copied, the clinical pathological process is highly matched with the stage progress characteristic of clinical chronic atrophic gastritis, and the model is high in success rate, good in stability and high in repeatability.

The invention relates to the technical field of medicines, in particular to application of polypeptide in prevention and / or treatment of gastrointestinal metaplasia. The polypeptide with the amino acid sequence of KIVFILCAAAAIVTRKT is found and verified for the first time and can target a molecular polypeptide of an intestinal key transcription factor CDX2 and a downstream signal channel of the CDX2, expression of the CDX2 and expression of the downstream signal channel of the CDX2 can be inhibited, expression of a stomach type marker can be promoted, the pathological process of GIM can be effectively reversed, and the GIM can be used for preparing a medicine for treating intestinal diseases. Compared with medicines which can only relieve symptoms or delay progression in the prior art, the medicine can realize pathological reversion of the GIM, so that a new direction can be provided for development of intervention medicines of the GIM.

The invention discloses a traditional Chinese medicine composition and application thereof in preparing a medicine for treating chronic atrophic gastritis and intestinal metaplasia. The traditional Chinese medicine composition is prepared from, by weight, 10-15 parts of radix pseudostellariae, 6-10 parts of poria cocos, 10-15 parts of roasted rhizoma atractylodis macrocephalae, 10-12 parts of pericarpium citri reticulatae, 6-9 parts of ginger processed pinellia, 10-15 parts of radix salviae miltiorrhizae, 15-30 parts of semen coicis, 15-30 parts of radix actinidiae chinensis, 10-15 parts of oldenlandia diffusa, 15 parts of actinidia valvata, 15-30 parts of wild grape roots, 2-3 parts of gecko and 3-6 parts of honey-fried licorice roots. The invention provides a new thought for early treatment of gastric mucosa atrophy and intestinal metaplasia so as to reduce the occurrence risk of gastric cancer and improve the living quality of patients.

The invention provides a co-culture method and application of mouse olfactory organoid and T cells. An age-related olfactory disorder (OD) organ model is constructed by co-culturing mouse olfactory organs and Th17 cells, and is used for exploring the pathogenesis of olfactory disorder, screening pathogenic genes and establishing a new method for treating olfactory disorder. Experimental results show that Tuj1 [+] and OMP [+] cells are significantly reduced after co-culture with Th17 cells; krt19 [+] cells are obviously increased and show strong intracellular staining, which indicates metaplasia and transformation; the contents of Muc5ac [+] mucus cells and secretions are increased; after 14 days of co-culture, both young and aged organs have obvious cystic structures, and the change of the aged organs is more obvious. Importantly, the IL-17a neutralizing antibody can effectively block the pedigree transformation to maintain the olfactory differentiation potential, so that the key effect of the IL-17a in regulating and controlling the cell fate decision is disclosed. It is shown that the inflammation microenvironment in the age-related OD patient can be simulated by co-culturing the olfactory organoid and the Th17 cells.

The disclosure provides methods for identifying genomic loci (e.g., vimentin and / or SqBE18) that are differentially methylated in metaplasias (e.g., Barrett's esophagus) and / or neoplastic cancers (e.g., esophageal cancers). Identification of methylated genomic loci has numerous uses, including for example, to characterize disease risk, to predict responsiveness to therapy, to non-invasively diagnose subjects and to treat subjects determined to have gastrointestinal metaplasias and / or neoplasias.

The invention discloses a stomach intestinal metaplasia grading method and system based on noise robustness and an open set, and belongs to the technical field of medical image processing. Processing the stomach endoscope image based on a pre-trained intestinal metaplasia grading model, and outputting an intestinal metaplasia grading result; the intestinal metaplasia grading model comprises a noise identification module, a comparison learning module, a label correction module and a classification output module; the pre-training process comprises the following steps: obtaining a clean sample set and a noise sample set based on a noise identification module; calculating class prototype similarity based on a comparative learning module, and discriminating valid noise and invalid noise; calculating an effective noise confidence coefficient based on a label correction module, and generating a differentiated pseudo label; and performing multi-module cooperative training based on the joint optimization total loss function, and outputting an intestinal metaplasia classification result through a classification output module. According to the method, the robustness of the model in noise and open set scenes is effectively improved, and the problem of 0-2-level fine-grained classification of intestinal metaplasia is solved.

The invention provides a traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia, which is prepared from 16 medicinal materials, namely ginseng, vinegar turtle shell, curcuma zedoary, astragalus membranaceus, bighead atractylodes rhizome, poria cocos, radix bupleuri, white paeony root, pericarpium citri reticulatae, rhizoma pinelliae preparata, angelica sinensis, moutan bark, fructus amomi, almond, cassia twig and honey-fried licorice root, and a specific process that the vinegar turtle shell is crushed to 3-5mm and then decocted is adopted. According to the treatment principle of tonifying qi, promoting tissue regeneration, dredging collaterals, removing food retention and guiding ascending and descending, astragalus membranaceus and ginseng are matched to tonify qi and promote mucosa regeneration; vinegar turtle shell and curcuma zedoary can enter collaterals to remove blood stasis and remove food retention; the almonds and the cassia twigs are matched to form a Qi movement guide of ventilating and dredging, so that the medicine accurately acts on the gastric submucosa. Through clinical observation of 120 patients with chronic atrophic gastritis accompanied with intestinal metaplasia, the total effective rate is 96.7%, the obvious effective rate is 91.7%, the mucosa improvement rate under a gastroscope is 92.5%, the intestinal metaplasia reversal rate is 68.3%, the recurrence rate is only 3.3% after 6 months, and the occurrence rate of liver and kidney dysfunction of the patients is 0%. The contrast experiment further proves that the intestinal metaplasia reversion rate is only 42.5% after the apricot kernels and the cassia twigs are removed. The traditional Chinese medicine composition can quickly reverse atrophy and intestinal metaplasia, promote mucosa repair, protect healthy qi and reduce relapse, and overcomes the defects that a traditional blood stasis dispersing and tonifying prescription is prone to injuring healthy qi, assists dampness and heat and is low in reversion rate.

The application belongs to the biological field and particularly relates to application of organic medlar polysaccharide in prevention and treatment of pancreatic acinar ductal metaplasia. Through in-vivo animal experiments, it is found that compared with common medlar polysaccharide, the organic medlar polysaccharide can significantly reduce the pancreatic acinar ductal metaplasia lesion area, can be used as a natural preparation for preventing pancreatic acinar ductal metaplasia, effectively improves the pancreatic acinar ductal metaplasia, and is used for reducing the incidence and progress risk of the pancreatic acinar ductal metaplasia.

The invention provides an asthma susceptibility gene, a medicine thereof and application of the medicine. The susceptibility gene is SGLT2. The medicine is an inhibitor canagliflozin of SGLT2. The potential causal association between the hypoglycemic drug canagliflozin and the asthma risk is found for the first time, the canagliflozin can significantly improve Th2 type airway inflammation, goblet cell metaplasia and pulmonary interstitial collagen deposition, the treatment effect is significant, and the anti-inflammatory protection effect is related to a PI3K / AKT pathway.

The present invention relates to a pharmaceutical composition for use in the treatment of a disease involving undesired migration, proliferation and / or metaplasia of retinal pigment epithelium (RPE) cells in a subject wherein the pharmaceutical composition comprises at least one epidermal growth factor receptor (EGFR) antagonist.

The disclosure provides methods for identifying genomic loci that are differentially methylated in neoplastic cancers, e.g., esophageal cancers. Identification of methylated genomic loci, and optionally in combination with the identification of somatic mutations in TP53, has numerous uses, including for example, to characterize disease risk, to predict responsiveness to therapy, to non-invasively diagnose subjects and to treat subjects determined to have gastrointestinal neoplasias.

The invention provides application of nicotinamide ribose in preparation of a medicine for treating pancreatic ductal adenocarcinoma and / or delaying the occurrence and development process of pancreatic ductal adenocarcinoma, and belongs to the technical field of biological medicine. Researches find that nicotinamide ribose (NR) treatment can effectively improve the sensitivity of pancreatic ductal adenocarcinoma tumor (PDAC) cells to gemcitabine, and NR and gemcitabine are combined to show a remarkable synergistic effect and remarkably promote tumor cell death. In a spontaneous PDAC model, NR single-drug treatment also shows an inhibition effect on the occurrence and development process of PDAC precancerous lesions. Specifically, the area of precancerous lesions such as acinus-catheter metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN) is effectively reduced, and the tumor-related fibrosis degree is relieved.